Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00316589 · ClinicalTrials.gov registry record · Phase 2
Safety and Immunogenicity of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in HIV Infected Patients
A Phase 2 study, sponsored by Bavarian Nordic.
- Completed
- Registry status
- Phase 2
- Development phase
- 581
- Enrollment target
NCT00316589 is a Phase 2 study that has completed, run by Bavarian Nordic. The registered enrollment target is 581 participants.
The verdict
NCT00316589, a Phase 2 study, has completed, sponsored by Bavarian Nordic.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 581 participants
- Enrollment target
Study Summary
The purpose of this study is to gather information on the safety and immunogenicity of an investigational smallpox vaccine in HIV infected populations. Subjects will receive two vaccinations
Interventions
- BIOLOGICAL IMVAMUNE (MVA-BN)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 581 participants |
| Start Date | 2006-06 |
| Est. Completion | 2009-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00316589
The ClinicalTrials.gov registry entry for NCT00316589 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 581 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bavarian Nordic, which has 41 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which IMVAMUNE (MVA-BN) is the first listed.
NCT00316589 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00316589 about?
NCT00316589 is a clinical study titled "Safety and Immunogenicity of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in HIV Infected Patients". The purpose of this study is to gather information on the safety and immunogenicity of an investigational smallpox vaccine in HIV infected populations. Subjects will receive two vaccinations
What is the current status of trial NCT00316589?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 581 participants. The study started on 2006-06. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00316589?
The interventions under investigation include: IMVAMUNE (MVA-BN) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00316589?
This trial is sponsored by Bavarian Nordic, which has 41 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.